Overview
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Description
Subjects with various CXCR4-related disease patients underwent 68Ga/18F-Pentixafor/Pentixather PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-Pentixafor/Pentixather PET/CT were calculated.
Eligibility
Inclusion Criteria:
- suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
- 18F-FDG PET/CT within two weeks
- signed written consent.
Exclusion Criteria:
- pregnancy
- breastfeeding
- known allergy against Pentixafor